ZEISS presents innovations that support ophthalmologists in their work
ZEISS announced innovations for clinical excellence and practice performance in ophthalmology. In the field of retina and glaucoma, doctors can expand their treatment option based on the innovative ZEISS AngioPlex OCT Angiography that provides three-dimensional representations of the retina and the choroid, eliminating the risk of adverse reactions caused by injections into the eye: Blood vessels can now be displayed using optical coherence tomography (OCT). Furthermore, two new fundus cameras offer more detailed views in the diagnosis and follow-up of eye diseases.
Cataract surgeons can profit from the introduction of the IOLMaster® 700 with SWEPT Source Biometry™ to the U.S. market which is designed to reduce the risk of refractive surprises due to incorrect measurements. It allows doctors to identify irregular geometries of the eye or insufficient fixation during the diagnostic exam
Additionally, the company reports on the minimally invasive refractive laser vision correction procedure SMILE. More than 300,000 eyes have been treated successfully with the procedure outside of the US. The fourth and last module of the Pre-Market Approval Application (PMA) was filed which is an important step in the FDA approval process.
Innovations for clinical excellence and practice performance in retina and glaucoma diagnosis and therapy
With the non-invasive AngioPlex OCT Angiography technique and two new high resolution fundus imaging solutions, ZEISS provides retina and glaucoma specialists with innovations that help them achieve very good outcomes for their patients.
Blood vessels can now be displayed using optical coherence tomography (OCT)
“We are proud to announce that ZEISS is the first company to bring the exciting new technology of OCT angiography to US customers. Our technology that can be easily integrated into routine clinical practice allows for earlier detection and management of micro-progressions based on ultra-clear 3D vascular images of the retina”, says Dr. Ludwin Monz, Chief Executive Officer of Carl Zeiss Meditec AG.
ZEISS AngioPlex OCT Angiography assists physicians in displaying the blood vessels of the patient's retina without having to inject fluorescent dye. The retina and choroid can be examined with the aid of optical coherence tomography (OCT) non-invasively in three-dimensional representations. This facilitates clinical decisions for physicians. AngioPlex is built on the proven CIRRUS platform and can thus easily be incorporated into clinical practice. The fast, single scan acquisition is no more difficult than a standard CIRRUS scan. “We hope the new non-invasive OCT angiography will become a routine imaging procedure in clinical practice”, says Dr. Ludwin Monz. It enables doctors to assess retinal microvasculature within the current workflow without the risks of dye injection: “This constitutes a real step forward for physicians and patients in non-invasive diagnosis of the eye”, Dr. Monz continues.
“AngioPlex OCT angiography will revolutionize the way we care for our patients. For diseases of the macula, AngioPlex will replace fluorescein and indocyanine green angiography because it is faster, cheaper, safer, non-invasive, doesn’t require dilation, and provides all the advantages of traditional OCT imaging while giving us superior images of the retinal and choroidal microvasculature”, says Dr. Philip J. Rosenfeld, Professor of Ophthalmology from the Bascom Palmer Eye Institute. He continues: “We can also segment different macular layers for better depth localization of diseases compared with angiography. Plus, in just a few seconds, it can be performed on the CIRRUS HD-OCT platform, and AngioPlex, along with FastTrac live tracking, provides motion free images for most patients, even the poor fixators. The potential for early detection and enhancing our treatment of microvascular diseases of the macula is tremendous. It’s an exciting time to be studying and treating retinal diseases in ophthalmology.”